Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Mankind Pharma Ltd Performance

Today's Low
2,310.00
arrowIcon
Today's High
2,350.00
52 Wk Low
1,242.00
arrowIcon
52 Wk High
2,410.00


Open

2348.25

Traded Value (Cr)

59.46 Cr

Prev. Close

2368.75

VWAP

2334.16

Volume

2,30,820

Face Value

1

Mankind Pharma Ltd Fundamentals

Market Cap
₹ 94,847 Cr
P/E Ratio (TTM)
54.92
P/B Ratio
11.25
Debt to Equity
0.02
ROE
18.48 %
EPS (TTM)
43.11
Dividend Yield
0.00%
Book Value
210.40

Click here to know more about Fundamentals

Mankind Pharma Ltd Financials

Mankind Pharma Ltd Financials

Mankind Pharma Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 74.88 % 76.50 % 76.50 % 76.50 %
FII 9.87 % 6.74 % 4.18 % 4.18 %
Mutual Funds 8.57 % 7.55 % 3.90 % 3.92 %
Others 5.46 % 8.07 % 14.31 % 14.38 %
Retail 1.22 % 1.14 % 1.11 % 1.02 %

Promoters

74.88%

FII

9.87%

Mutual Funds

8.57%

Others

5.46%

Retail

1.22%

Promoters

76.50%

FII

6.74%

Mutual Funds

7.55%

Others

8.07%

Retail

1.14%

Promoters

76.50%

FII

4.18%

Mutual Funds

3.90%

Others

14.31%

Retail

1.11%

Promoters

76.50%

FII

4.18%

Mutual Funds

3.92%

Others

14.38%

Retail

1.02%

Resistance and Support

₹2,212.97

PIVOT

resistance-arrow
Resistance
First Resistance₹2,270.933
Second Resistance₹2,327.967
Third Resistance₹2,385.933
support-arrow
Support
First Resistance₹2,155.933
Second Resistance₹2,097.967
Third Resistance₹2,040.933
RSI70.198
MACD112.112
ADX22.283
CCI48.070

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day230,820164,90564.35
Week340,553163,07452.82
1 Month1,329,796923,84557.45
6 Months230,82090,79739.34

About Mankind Pharma Ltd

Mankind Pharma Ltd. was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind' tablets and Glimestar' tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops' and Tobastar Eye Drops'. In 2007, the Company entered the consumer healthcare segment with the launch of Manforce' brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories. It entered into the business of animal healthcare segment and launched Bandykind' and Ceftiforce'. It established their Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh in year 2009. It launched the brand, Preganews' into the consumer healthcare segment in year, 2010. In 2012, it set up their first R&D centre at IMT Manesar, in Haryana. Thereafter, in year 2014, the Company acquired Shree Jee Laboratory Private Limited along with its API manufacturing site at Behror, Rajasthan. It set up the Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh. In 2015, subsidiaries like Lifestar Pharma LLC in the US and Mankind Pharma Pte. Limited in Singapore were formed into with the Company. In 2017, a new manufacturing facility got established in Sikkim. In 2019, the Company entered into female infertility business segment and launched Dydroboon' tablets. In 2020, a subsidiary, Lifestar Pharmaceuticals Private Limited was formed in Nepal. The Company introduced a specialty therapeutic division for cardiovascular diseases (CVD) drugs segment and launched Cilaheart' tablets and Statpure' tablets in the market. It launched Zukanorm' tablets for diabetes pharmaceuticals segment. Another new subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE got incorporated during the year 2021. It launched Mlife' tablets in the specialty division for therapeutic respiratory pharmaceuticals. It entered into specialty therapeutic neuro/central nervous system pharmaceuticals segment business with the launch of Trugaba-NT' tablets and Prebris-MNT' tablets. In 2022, the Company acquired formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited. Further, it entered into the transplant segment with the launch of Pangraf Capsules' and Mycept' tablets. It entered into the business of oncology segment with the launch of injection Pacliall'. It acquired Daffy' and Combihale' brands from Dr. Reddy's Laboratories. The Company operate 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022. Their formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022. The Company is planning to raise capital from Public by issuing 40,058,844 Equity Shares through Offer for Sale.

Managing Director

RAJEEV JUNEJA

Founded

1991

NSE Symbol

MANKIND

Mankind Pharma Ltd Management

NameDesignation
RAMESH CHAND JUNEJAChairman & Wholetime Director
RAJEEV JUNEJAVice Chairman & M.D.
SHEETAL ARORAWhole Time Director & CEO
TILOKCHAND PUNAMCHAND OSTWALIndependent Director
Pradeep ChughCompany Sec. & Compli. Officer
Bharat AnandIndependent Director
SATISH KUMAR SHARMAWhole-time Director
Vivek KalraIndependent Director
Vijaya SampathIndependent Director

Mankind Pharma Ltd News

Mankind Pharma Ltd spurts 1.56%, up for third straight session
Mankind Pharma Ltd is quoting at Rs 2395.3, up 1.56% on the day as on 12:49 IST on the NSE. The stock is up 68.41% in last one year as compared to a 28.76% gain in NIFTY and a 56% gain in the Nifty Pharma index.
Board of Mankind Pharma approves slump sale of OTC biz
At meeting held on 02 April 2024
Mankind Pharma gains after board OKs to sell OTC biz to subsidiary
Mankind Pharma jumped 2.53% to Rs 2,370.80 after the company’s board approved the sale of Over the Counter (OTC) business of the company to wholly owned subsidiary company on slump sales basis.
Volumes spurt at Mankind Pharma Ltd counter
Mankind Pharma Ltd notched up volume of 150.98 lakh shares by 14:14 IST on NSE, a 30.81 fold spurt over two-week average daily volume of 4.90 lakh shares
Volumes spurt at Mankind Pharma Ltd counter
Mankind Pharma Ltd registered volume of 7.38 lakh shares by 10:46 IST on BSE, a 38.68 fold spurt over two-week average daily volume of 19071 shares
Mankind Pharma consolidated net profit rises 59.69% in the December 2023 quarter
Sales rise 24.68% to Rs 2606.96 crore
Mankind Pharma to convene board meeting
On 31 January 2024
Mankind Pharma hikes stake in Actimed Therapeutics to 10.19%
Mankind Pharma said that it has made investment of GBP 999,900 (approximately Rs 10.52 crore) in Actimed Therapeutics for acquiring additional 1.29% of its paid-up ordinary share capital.
Volumes jump at Mankind Pharma Ltd counter
Mankind Pharma Ltd saw volume of 259.4 lakh shares by 14:14 IST on NSE, a 110.22 fold spurt over two-week average daily volume of 2.35 lakh shares
Mankind Pharma Q2 PAT rises 19% YoY to Rs 501 cr
The pharmaceutical company reported 19.4% increase in consolidated net profit to Rs 501.03 crore in Q2 FY23 as against Rs 419.71 crore posted in Q2 FY23.

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,69,497 Cr
₹ 1,540.00
(-3.99 %)
89.67
CIPLA₹ 1,12,773 Cr
₹ 1,396.80
(-1.84 %)
34.28
DRREDDY₹ 1,01,489 Cr
₹ 6,083.85
(-1.20 %)
25.50
DIVISLAB₹ 1,00,339 Cr
₹ 3,779.70
(1.09 %)
73.55
ZYDUSLIFE₹ 96,814 Cr
₹ 962.15
(-3.22 %)
35.99

Mankind Pharma Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Mankind Pharma Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Mankind Pharma Ltd's share price is ₹2,320.35 as of April 12, 2024

Mankind Pharma Ltd's P/E ratio is 54.92 times as of April 12, 2024.

Mankind Pharma Ltd's most recent financial reports indicate a price-to-book ratio of 11.25, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Mankind Pharma Ltd's market is 94,847 Cr as on April 12, 2024.

The current financial records of Mankind Pharma Ltd show a 18.48% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Mankind Pharma Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Mankind Pharma Ltd's 52-week high and low as of April 12, 2024 are ₹2350 and ₹2310 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Mankind Pharma Ltd stands at 74.88%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 6.74% to 9.87%.